Immune alterations and emerging immunotherapeutic approaches in lung cancer

Bibliography

• Jemal A, Siegel R, Xu J, Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Yagui-Beltran A, Jablons DM. A translational approach to lung cancer research. Ann Thorac Cardiovasc Surg 2009;15:213-20
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Bepler G, Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801
   PubMed Web of Science ®Google Scholar
• Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer 2007;7:778-90
   PubMed Web of Science ®Google Scholar
• Van den Heuvel MM, Burgers SA, van Zandwijk N. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clin Lung Cancer 2009;10:99-105
   PubMed Web of Science ®Google Scholar
• Sterlacci W, Wolf D, Savic S, High transforming growth factor beta expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 2012;43:339-49
   PubMed Web of Science ®Google Scholar
• Sato Y, Mukai K, Watanabe S, Lymphocyte subsets in pulmonary venous and arterial blood of lung cancer patients. Jpn J Clin Oncol 1989;19:229-36
   PubMed Web of Science ®Google Scholar
• Wesselius LJ, Wheaton DL, Manahan-Wahl LJ, Lymphocyte subsets in lung cancer. Chest 1987;91:725-9
   PubMed Web of Science ®Google Scholar
• Lucivero G, Pierucci G, Bonomo L. Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J 1988;1:337-40
   PubMed Web of Science ®Google Scholar
• Zikos TA, Donnenberg AD, Landreneau RJ, Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 2011;60:819-27
   PubMed Web of Science ®Google Scholar
• Zhuang X, Xia X, Wang C, High number of CD8+ T cells in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010;18:24-8
   PubMedGoogle Scholar
• Karagoz B, Bilgi O, Gumus M, CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 2010;27:29-33
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Zhou Q, Zhang JC, CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res 2011;12:77
   PubMedGoogle Scholar
• Li Y, Cao ZY, Sun B, Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther 2011;12:610-16
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6
   PubMed Web of Science ®Google Scholar
• Li H, Zhao H, Yu J, Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother 2011;60:1587-96
   PubMed Web of Science ®Google Scholar
• Schneider T, Kimpfler S, Warth A, Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 2011;6:432-8
   PubMed Web of Science ®Google Scholar
• Eikawa S, Ohue Y, Kitaoka K, Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 2010;185:6734-40
   PubMed Web of Science ®Google Scholar
• Shimizu K, Nakata M, Hirami Y, Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-90
   PubMed Web of Science ®Google Scholar
• Anz D, Mueller W, Golic M, CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer 2011;129:2417-26
   PubMed Web of Science ®Google Scholar
• Karagoz B, Bilgi O, Gumus M, CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 2010;27:29-33
   PubMed Web of Science ®Google Scholar
• Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol 2008;69:811-14
   Google Scholar
• Wang YY, He XY, Cai YY, The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN. Target Oncol 2011;6:147-54
   PubMed Web of Science ®Google Scholar
• Gorny MK, Jezewska E, Skrzypczak A, Immunoregulatory effect of T cell subsets on PWM-induced IgG synthesis by blood lymphocytes in lung cancer. Arch Immunol Ther Exp (Warsz) 1991;39:243-52
   PubMedGoogle Scholar
• Takahashi T, Tagami T, Yamazaki S, Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-10
   PubMed Web of Science ®Google Scholar
• Miotto D, Lo Cascio N, Stendardo M, CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer 2010;69:355-60
   PubMed Web of Science ®Google Scholar
• Venkataraman M, Rao DS, Iyer BS, The functional deficiency of B lymphocytes in patients with lung cancer is due to inadequate T-cell help and excessive suppression by T and non-T cells. Cancer Invest 1989;7:7-16
   PubMed Web of Science ®Google Scholar
• van der Vliet HJ, Koon HB, Atkins MB, Exploiting regulatory T-cell populations for the immunotherapy of cancer. J Immunother 2007;30:591-5
   PubMed Web of Science ®Google Scholar
• Sorrentino R, Morello S, Forte G, B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med 2011;183:1369-79
   Google Scholar
• Yasuda M, Takenoyama M, Obata Y, Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. Cancer Res 2002;62:1751-6
   PubMed Web of Science ®Google Scholar
• Yuan D, Koh CY, Wilder JA. Interactions between B lymphocytes and NK cells. FASEB J 1994;8:1012-18
   PubMed Web of Science ®Google Scholar
• Brunda MJ, Luistro L, Warrier RR, Antitumor and antimetastatic activity of interleukin 12 against murine tremors. J Exp Med 1993;178:1223-30
   PubMed Web of Science ®Google Scholar
• Jones HP, Wang YC, Aldridge B, Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses. Cancer Immun 2008;8:4
   PubMedGoogle Scholar
• Quan N, Zhang Z, Demetrikopoulos MK, Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Cancer Res 1999;59:1080-9
   PubMed Web of Science ®Google Scholar
• Guo Y, Wu M, Chen H, Effective tumor vaccine generated by fusion of hepatoma cells with activated B-lymphocytes. Science (Washington DC) 1994;263:518-20
   PubMed Web of Science ®Google Scholar
• Le Maux Chansac B, Moretta A, Vergnon I, NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005;175:5790-8
   PubMed Web of Science ®Google Scholar
• Al Omar SY, Marshall E, Middleton D, Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology 2011;133:94-104
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011;71:5412-22
   PubMed Web of Science ®Google Scholar
• Kim H, Kim SH, Kim MJ, EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother 2011;34:372-81
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-69
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang J, Chen S, Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011;74:188-96
   PubMed Web of Science ®Google Scholar
• Sawachi K, Shimada Y, Taniguchi H, Cytotoxic effects of activated alveolar macrophages on lung carcinoma cells via cell-to-cell contact and nitric oxide. Anticancer Res 2010;30:3135-41
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Shimada Y, Sawachi K, Lipopolysaccharide-activated alveolar macrophages having cytotoxicity toward lung tumor cells through cell-to-cell binding-dependent mechanism. Anticancer Res 2010;30:3159-65
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Chen YY, Muthana M, Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011;186:4183-90
   PubMed Web of Science ®Google Scholar
• White ES, Strom SR, Wys NL, Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol 2001;166:7549-55
   PubMed Web of Science ®Google Scholar
• Ungefroren H, Sebens S, Seidl D, Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011;9:18
   PubMedGoogle Scholar
• Fritz JM, Dwyer-Nield LD, Malkinson AM. Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation. Mol Cancer 2011;10:76
   PubMed Web of Science ®Google Scholar
• Standiford TJ, Kuick R, Bhan U, TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 2011;30:2475-84
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Zenmyo M, Watari K, Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008;99:1595-602
   PubMed Web of Science ®Google Scholar
• Ibaraki T, Muramatsu M, Takai S, The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2005;28:617-21
   PubMed Web of Science ®Google Scholar
• Stoyanov E, Uddin M, Mankuta D, Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer 2012;75:38-44
   PubMed Web of Science ®Google Scholar
• Tataroglu C, Kargi A, Ozkal S, Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer 2004;43:47-54
   PubMed Web of Science ®Google Scholar
• Carlini MJ, Dalurzo MC, Lastiri JM, Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol 2010;41:697-705
   PubMed Web of Science ®Google Scholar
• Dundar E, Oner U, Peker BC, The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. J Int Med Res 2008;36:88-95
   PubMed Web of Science ®Google Scholar
• Imada A, Shijubo N, Kojima H, Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 2000;15:1087-93
   PubMed Web of Science ®Google Scholar
• Ilie M, Hofman V, Ortholan C, Predictive clinical outcome of the intratumoral CD66b-positive neutrophil- to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 2012;118:1726-37
   PubMed Web of Science ®Google Scholar
• Vikis HG, Gelman AE, Franklin A, Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis. Mol Carcinog 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Tomita M, Shimizu T, Ayabe T, Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 2011;31:2995-8
   PubMed Web of Science ®Google Scholar
• Tazzyman S, Barry ST, Ashton S, Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer 2011;129:847-58
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Palladino GP, Lacedonia D, Neutrophilic airways inflammation in lung cancer: the role of exhaled LTB-4 and IL-8. BMC Cancer 2011;11:226
   PubMed Web of Science ®Google Scholar
• Rotondo R, Barisione G, Mastracci L, IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer 2009;125:887-93
   PubMed Web of Science ®Google Scholar
• Halder SK, Cho YJ, Datta A, Elucidating the mechanism of regulation of transforming growth factor beta Type II receptor expression in human lung cancer cell lines. Neoplasia 2011;13:912-22
   PubMed Web of Science ®Google Scholar
• Gonzalez-Santiago AE, Mendoza-Topete LA, Sanchez-Llamas F, TGF-beta1 serum concentration as a complementary diagnostic biomarker of lung cancer: establishment of a cut-point value. J Clin Lab Anal 2011;25:238-43
   PubMed Web of Science ®Google Scholar
• Xu CC, Wu LM, Sun W, Effects of TGF-beta signaling blockade on human A549 lung adenocarcinoma cell lines. Mol Med Rep 2011;4:1007-15
   Web of Science ®Google Scholar
• Zhang HJ, Wang HY, Zhang HT, Transforming growth factor-beta1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition. Mol Cell Biochem 2011;355:309-14
   PubMed Web of Science ®Google Scholar
• Chow G, Tauler J, Mulshine JL. Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol 2010;2010:485468
   PubMedGoogle Scholar
• Felaco P, Castellani ML, De Lutiis MA, IL-32: a newly-discovered proinflammatory cytokine. Biol Regul Homeost Agents 2009;23:141-7
   PubMed Web of Science ®Google Scholar
• Sculier JP, Berghmans T, Meert AP. Update in lung cancer and mesothelioma 2009. Am J Respir Crit Care Med 2010;181:773-81
   PubMed Web of Science ®Google Scholar
• Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009;180:769-79
   PubMed Web of Science ®Google Scholar
• Chen X, Xie Q, Cheng X, Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010;101:2384-90
   PubMed Web of Science ®Google Scholar
• Chen X, Wan J, Liu J, Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010;69:348-54
   PubMed Web of Science ®Google Scholar
• Ankathatti Munegowda M, Deng Y, Mulligan SJ, Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother 2011;60:1473-84
   PubMed Web of Science ®Google Scholar
• Carmi Y, Rinott G, Dotan S, Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 2011;186:3462-71
   PubMed Web of Science ®Google Scholar
• WangJ, Ding Q, Shi Y, The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis 2012;27:305-12
   PubMed Web of Science ®Google Scholar
• Miotto D, Lo Cascio N, Stendardo M, CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer 2010;69:355-60
   PubMed Web of Science ®Google Scholar
• Zeng L, O'Connor C, Zhang J, IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 2010;49:294-302
   PubMed Web of Science ®Google Scholar
• Ho MY, Leu SJ, Sun GH, IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009;183:6217-26
   PubMed Web of Science ®Google Scholar
• Tyagi A, Agarwal C, Dwyer-Nield LD, Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Park SY, Lee HS, Jang HJ, Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thorac Surg 2011;91:1668-73
   PubMed Web of Science ®Google Scholar
• Wang J, Cao C, Luo H, Tumour necrosis factor alpha -308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet 2011;38:311-20
   PubMed Web of Science ®Google Scholar
• Shen CH, Talay O, Mahajan VS, Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues. Proc Natl Acad Sci USA 2010;107:22587-92
   PubMed Web of Science ®Google Scholar
• Bergeron A, El-Hage F, Kambouchner M, Characterisation of dendritic cell subsets in lung cancer micro-environments. Eur Respir J 2006;28:1170-7
   PubMed Web of Science ®Google Scholar
• Schneider T, Hoffmann H, Dienemann H, Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011;6:1162-8
   PubMed Web of Science ®Google Scholar
• Hsu YL, Huang MS, Cheng DE, Lung tumor-associated dendritic cell-derived amphiregulin increased cancer progression. J Immunol 2011;187:1733-44
   PubMed Web of Science ®Google Scholar
• Condon TV, Sawyer RT, Fenton MJ, Lung dendritic cells at the innate-adaptive immune interface. J Leukoc Biol 2011;90:883-95
   PubMed Web of Science ®Google Scholar
• Mu CY, Huang JA, Chen Y, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-8
   PubMed Web of Science ®Google Scholar
• Kato M, Nakamura Y, Suda T, Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells. Cancer Immunol Immunother 2011;60:1029-38
   PubMed Web of Science ®Google Scholar
• Zhong R, Teng J, Han B, Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011;60:1497-502
   PubMed Web of Science ®Google Scholar
• Chen J, Cao X, Xiu Q. Treatment of spontaneous metastatic lung cancer with tumor antigen-pulsed, interleukin-18 gene-modified dendritic cells. Zhonghua Yi Xue Za Zhi 2001;81:779-82
   PubMedGoogle Scholar
• Yadav A, Kumar B, Datta J, IL-6 Promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011;9:1658-67
   PubMed Web of Science ®Google Scholar
• Heinrich EL, Walser TC, Krysan K, The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviron 2011; [Epub ahead of print]
   PubMedGoogle Scholar
• Gastman BR, Atarashi Y, Reichert TE, Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356-64
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010;125:S272-83
   PubMed Web of Science ®Google Scholar
• Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008;222:145-54
   PubMed Web of Science ®Google Scholar
• Marincola FM, Jaffee EM, Hicklin DJ, Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
   PubMedGoogle Scholar
• West HJ. Novel targeted agents for lung cancer. Clin Lung Cancer 2009;10:S41-6
   PubMed Web of Science ®Google Scholar
• Qiao G, Li Z, Molinero L, T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol 2008;28:2470-80
   PubMed Web of Science ®Google Scholar
• Otsuka S, Bebb G. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J Thorac Oncol 2008;3:1379-83
   PubMed Web of Science ®Google Scholar
• Burger JA, Stewart DJ, Wald O, Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 2011;11:621-30
   PubMed Web of Science ®Google Scholar
• Probst HC, McCoy K, Okazaki T, Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005;6:280-6
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ishii G, Taira T, Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients. J Thorac Oncol 2011;6:1460-7
   PubMed Web of Science ®Google Scholar
• Kawase A, Ishii G, Nagai K, Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008;123:1053-9
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko IN, Luft A, Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). 2010 ASCO Ann Meeting Proc 28. J Clin Oncol 2010;15:7531
   Google Scholar
• Brahmer JR, Drake CG, Wollner I, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75
   PubMed Web of Science ®Google Scholar
• Flies DB, Sandler BJ, Sznol M, Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 2011;84:409-21
   PubMedGoogle Scholar
• Parikh PM, Vaid A, Advani SH, Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011;29:4129-36
   PubMed Web of Science ®Google Scholar
• Digumarti R, Wang Y, Raman G, A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011;6:1098-103
   PubMedGoogle Scholar
• Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-17
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28:4769-77
   PubMed Web of Science ®Google Scholar
• Kaur A, Dasanu CA. Rapidly progressive colonic dysplasia/neoplasia in a series of treated lung cancer patients: is paclitaxel involved? J Oncol Pharm Pract 2012; [Epub ahead of print]
   PubMedGoogle Scholar
• Neuville M, Borie R, Rodier JM, Pneumocystis pneumonia in a patient treated with pemetrexed for non small cell lung cancer. Rev Mal Respir 2011;28:97-100
   PubMed Web of Science ®Google Scholar